Please enable JavaScript.

Coggle requires JavaScript to display documents.

mAb (LESS. 11) - Coggle Diagram

- - - - activating- mutations (ICD), amplifications (overexpression), translocations
    - - against ATP-pocket: COMPETITIVE, NONCOMP., ALLOSTERIC, IRREVERSIBLE
        
        non-small cell lung cancer, affect kin. domain: gefi-/erlo-/afa-/osimer (overcomes T790M)-tinib
      - against R-ECD mAb (colorectal cancer, WT-KRAS): cetuximab (+FOLFIRI), panatimumab
    - - ECD (trastuzumab (DIV, ADCC, cardiotoxicity); margetuximab (DIV, just cancer ccs) pertuzumab (DII, cardiotoxicity), tr. emtansine(microtubuli) / deruxtecan(no R dimerization + blocks topoisomerasi I); zanidatamab (DII, DIV)
    - - imatinib (also KIT, PDGFR)/nilotinib; dasatinib, ponatinib/asciminib (T315I)
  - - - atezolizumab
    - - ipilimumab (autoimmune deseases)
    - - nivolumab,pembrolizumab
- - - - ADEPT (antibody directed enzyme prodrug theraphy)
      - RADIONUCLIDE, SMALL MOL, TOXIN
    - - ADCC (nk) / CDC
- - - - impair drug efficacy
      - SEVERE ADR if binds endogenous counterpart
    - - related to: treatment, patient, product